Entity

Time filter

Source Type

Kollam District, India

Jyothi M.,Providence College | Sanil R.,Government Arts College | Shashidhar S.,Azeezia Medical College
Indian Journal of Ophthalmology | Year: 2011

Context: Glutathione depletion has been postulated to be the prime reason for galactose cataract. The current research seeks the prospect of targeting erythrocytes to pursue the lens metabolism by studying the glutathione system. Aims: To study the activity of the glutathione-linked scavenger enzyme system in the erythrocyte and lens of rats with cataract. Materials and Methods: Experiments were conducted in 36 male albino rats weighing 80 20 g of 28 days of age. The rats were divided into two major groups, viz. experimental and control. Six rats in each group were sacrificed every 10 days, for 30 days. Cataract was induced in the experimental group by feeding the rats 30% galactose (w/w). The involvement of reduced glutathione (GSH) and the linked enzymes was studied in the erythrocytes and lens of cataractous as well as control rats. Statistical Analysis: Parametric tests like one-way ANOVA and Student's 't' test were used for comparison. Correlation linear plot was used to compare the erythrocyte and lens metabolism. Results: Theconcentration of GSH and the activity of linked enzymes were found decreased with the progression of cataract, and also in comparison to the control. The same linear fashion was also observed in the erythrocytes. Conclusion: Depletion of GSH was the prime factor for initiating galactose cataract in the rat model. This depletion may in turn result in enzyme inactivation leading to cross-linking of protein and glycation. The correlation analysis specifies that the biochemical mechanism in the erythrocytes and lens is similar in the rat model. Source


Latha M.S.,Dr. Reddys Laboratories Ltd | Martis J.,Fr Muller Medical College | Shobha V.,Fr Muller Medical College | Shinde R.S.,Dr. Reddys Laboratories Ltd | And 6 more authors.
Journal of Clinical and Aesthetic Dermatology | Year: 2013

The increasing incidence of skin cancers and photodamaging effects caused by ultraviolet radiation has increased the use of sunscreening agents, which have shown beneficial effects in reducing the symptoms and reoccurrence of these problems. Many sunscreen compounds are in use, but their safety and efficacy are still in question. Efficacy is measured through indices, such as sun protection factor, persistent pigment darkening protection factor, and COLIPA guidelines. The United States Food and Drug Administration and European Union have incorporated changes in their guidelines to help consumers select products based on their sun protection factor and protection against ultraviolet radiation, whereas the Indian regulatory agency has not yet issued any special guidance on sunscreening agents, as they are classified under cosmetics. In this article, the authors discuss the pharmacological actions of sunscreening agents as well as the available formulations, their benefits, possible health hazards, safety, challenges, and proper application technique. New technologies and scope for the development of sunscreening agents are also discussed as well as the role of the physician in patient education about the use of these agents. Source


Linu M.,Kerala University | Shankar S.,Azeezia Medical College
Research Journal of Biotechnology | Year: 2012

As part of a permanent screening programme, which considers the search for plants and natural products with anticancer properties, the plants are subjected to bioscreening assay testing for cytotoxity. Another crucial component of pre-clinical oncology drug development is the study and monitoring of cell death in tumour and normal tissues. Therefore, methanolic extract stem bark of cassia fistula L was tested for in vitro cytotoxicity and apoptogenic potential by MTT assay, DAPI assay, mitosensor assay and caspase assay. Source


Naik H.G.,Azeezia Medical College | Kolur A.,Azeezia Medical College | Maled D.,Institute of Medical science and Research IMSR | Khanwelkar C.C,Krishna University | And 2 more authors.
National Journal of Physiology, Pharmacy and Pharmacology | Year: 2014

Background: Poloxamer 407 is used in parenteral formulations as solubilizing and wetting agent for traditional, low-molecular-weight organic drug molecules and as stabilizing agent for proteins and polypeptide drugs. It has very high promising value in the medicine field, but has held responsible for changes in the lipid parameters. Thus, effect of poloxamer 407 on the rabbit’s serum very low density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels was studied after being injected intravenously.Aims & Objective: To study the effect of poloxamer 407 on rabbit’s serum VLDL, LDL, and HDL levels following intravenous injection.Materials and Methods: Pretreatment, baseline readings were recorded. Rabbits were injected with 5.5, 27.5, and 137.5 mg/kg of poloxamer 407, and the effects on blood chemistry were assessed on the 2nd, 4th, and 7th day. The results of the study were expressed as mean ± SEM, and data were analyzed using one-way analysis of variance test. Values with P < 0.05 were considered as significant.Results: The highest dose of poloxamer 407 (137.5 mg/kg) significantly increased serum VLDL and decreased HDL level in rabbits, with the maximum increase observed on the 2nd day after injection. All the doses given did not alter the serum LDL level. The lower doses of poloxamer 407 did not alter serum VLDL, LDL, and HDL levels.Conclusion: Our results showed that poloxamer 407 in higher doses significantly increased serum VLDL and decreased HDL levels but in lower doses did not show any adverse effect on the lipid biochemistry. But we recommend further studies to know the effect of this poloxamer on chronic use and through different route of administration. © 2014, Mrs Deepika Charan. All rights reserved. Source


Abideen S.,Azeezia Medical College | Vivekanandan K.,Indian Pharmacopoeia Commission | Mishra P.,SEARPharm Forum
Asian Journal of Pharmaceutical and Clinical Research | Year: 2015

Background: Critically ill-patients frequently receive multidrug regimens (polypharmacy) with the goal of providing the superlative pharmacotherapeutic support. Drug-drug interaction (DDI) is a specific type of adverse event, which develops due to multiple regimen therapy, and that may lead to significant hospitalization and death. Methods: A retrospective study was conducted for a period of 3 months to assess the prevalence potential DDIs in medical Intensive Care Unit (MICU) patients of a north Indian tertiary care hospital using Lexi Comp drug interact android mobile application. Results: A total of 72 patients were identified for this study. 65.27% (47) were males, and 34.72% (25) were females. The average age of the study population was 52 years, and average length of stay in hospital was found to be 7 days. An average of 17.09 drugs per patient was administered to the patients during the study period. 90.02% (65) of patients experienced at least one potential DDI. A total of 222 interactions observed during the study period with an occurrence rate of 3.08 DDI per patient. There were 106 types drug pairs was found to get interacted at least 1 time. Corticosteroids, anticonvulsants, central nervous system depressants, sympathomimetics and quinolone antibiotics are the main class of drugs mostly interacted in MICU. Conclusion: The study shows that, concomitant administration rate of potentially interacting drugs are very high in MICU. We suggest that, special safety measures must be followed by physicians, pharmacists, and nurses to prevent and monitor DDIs in all departments of the hospital especially in intensive care departments. Health providers must be able to identify and classify drug interactions (DIs), and know how to manage them clinically, that is, how to minimize or more over prevent them. Practice of a computer assisted DI checker before prescribing/administering of the drugs can avoid DDIs. In settings with multiple drug use like in ICUs, attendance of a pharmacist or clinical pharmacist, taking the responsibility for monitoring DIs and notifying the physician about potential problems could decrease the harm inpatient and ensure the patient safety. © 2015, Asian Journal of Pharmaceutical and Clinical Research. All rights reserved. Source

Discover hidden collaborations